Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

BACKGROUND: Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locally advanced or metastatic EGA with a doublet chemotherapy consisting of a platinum compound and a fluoropyrimidine in combination with trastuzumab for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tintelnot, Joseph, Goekkurt, Eray, Binder, Mascha, Thuss-Patience, Peter, Lorenzen, Sylvie, Knorrenschild, Jorge Riera, Kretzschmar, Albrecht, Ettrich, Thomas, Lindig, Udo, Jacobasch, Lutz, Pink, Daniel, Al-Batran, Salah-Eddin, Hinke, Axel, Hegewisch-Becker, Susanna, Nilsson, Sven, Bokemeyer, Carsten, Stein, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268753/
https://www.ncbi.nlm.nih.gov/pubmed/32487035
http://dx.doi.org/10.1186/s12885-020-06958-3

Ejemplares similares

Ejemplares similares